Financial Performance - As of September 30, 2025, CervoMed had approximately $27.3 million in cash, cash equivalents, and marketable securities, down from $38.9 million as of December 31, 2024[4]. - Grant revenue for the three months ended September 30, 2025, was approximately $0.3 million, a decrease from approximately $1.9 million for the same period in 2024, due to the completion of the initial phase of the RewinD-LB trial[5]. - Net loss for the three months ended September 30, 2025, was approximately $7.7 million, compared to a net loss of approximately $4.8 million for the same period in 2024[8]. - Total operating expenses increased to $8,366,768 in Q2 2025 from $7,336,024 in Q2 2024, marking a rise of approximately 14.1%[17]. - Net loss for Q2 2025 was $7,726,639, compared to a net loss of $4,753,541 in Q2 2024, indicating an increase in losses of about 62.5%[17]. - Total comprehensive loss for the first half of 2025 was $18,929,450, compared to $9,461,619 in the first half of 2024, indicating a year-over-year increase of approximately 99.5%[17]. - Interest income decreased to $318,787 in Q2 2025 from $646,172 in Q2 2024, a decline of about 50.7%[17]. - Net loss per share for Q2 2025 was $0.84, compared to $0.55 in Q2 2024, representing a decline of 52.7%[17]. - CervoMed's total stockholders' equity decreased to approximately $26.0 million as of June 30, 2025, from $39.2 million as of December 31, 2024[15]. Research and Development - Research and Development (R&D) expenses for the quarter ended September 30, 2025, were approximately $6.0 million, an increase from approximately $5.1 million in the same period in 2024[7]. - Research and development expenses rose to $6,040,442 in Q2 2025 from $5,125,097 in Q2 2024, reflecting an increase of approximately 17.9%[17]. - The 32-week treatment data from the Phase 2b RewinD-LB trial showed a 64% risk reduction in clinically significant worsening compared to control over 32 weeks of neflamapimod treatment (p<0.001)[6]. - CervoMed plans to initiate a global pivotal Phase 3 trial for neflamapimod in DLB in the second half of 2026[1]. - The company received a $21.0 million grant from the National Institute on Aging in January 2023 to support the RewinD-LB trial[5]. - The company is preparing for a global pivotal trial initiation and meeting with global regulators in the coming months[1]. General and Administrative Expenses - General and Administrative (G&A) expenses were approximately $2.3 million during the three months ended September 30, 2025, compared to approximately $2.2 million in the same period in 2024[8]. - General and administrative expenses rose to $2,326,326 in Q2 2025 from $2,210,927 in Q2 2024, reflecting an increase of about 5.2%[17]. Grant Revenue - Grant revenue for Q2 2025 was $322,569, compared to $1,939,751 in Q2 2024, representing a significant decline[17]. - Total other income, net for Q2 2025 was $317,560, compared to $642,732 in Q2 2024, indicating a decrease of approximately 50.6%[17]. Shareholder Information - Weighted average shares outstanding increased to 9,252,719 in Q2 2025 from 8,702,764 in Q2 2024, an increase of approximately 6.3%[17].
DIFFUSION PHARMA(DFFN) - 2025 Q3 - Quarterly Results